Infectious Disease Division, Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, King Fahad Hospital of the University, Dammam, Al-Khobar, Saudi Arabia.
Department of Microbiology, King Fahad Hospital of the University, Al-Khobar, Saudi Arabia.
Antimicrob Resist Infect Control. 2023 Nov 19;12(1):128. doi: 10.1186/s13756-023-01338-5.
Despite tremendous efforts to prevent central line-associated bloodstream infections, they still remain life-threatening complications among hospitalized patients with significant morbidity and mortality worldwide. The emerging antibiotic-resistant bacteria and other risk factors, including patient comorbidities, complicate patient management.
A single-center retrospective observational study was conducted at King Fahad Hospital of the University, Eastern Province, Saudi Arabia. Hospitalized patients with confirmed central line-associated bloodstream infections between January 2015 and December 2020 were included. The primary objectives were to investigate the trends in antibiotic susceptibility patterns of the causative agents, coexisting comorbid conditions, and other risk factors associated with mortality.
A total of 214 patients with confirmed central line-associated bloodstream infections were included (CLABSI). The overall 30-day mortality rate was 33.6%. The infection rates per 1000 central line days for medical, surgical, and pediatric intensive care units were 4.97, 2.99, and 4.56 per 1000 CL days, respectively. The overall microbiological trends showed a predominance of Gram-negative agents, a steady increase of fungal CLABSI up to 24.0% in 2020, and a high prevalence of multidrug resistance up to 47% of bacterial CLABSI. In addition, the study indicates a significant negative surviving correlation with diabetes mellitus, cardiovascular disease, lung disease, chronic kidney disease, and the presence of ≥ 3 comorbidities (P < 0.05).
The microbiological trends of the study population demonstrated a steady increase of CLABSI caused by Candida spp. with a predominance of Gram-negative pathogens. Stratifying the patients according to relevant mortality risk factors, including patient comorbidities, will help reduce CLABSI rates and improve patient outcomes.
尽管在预防中心静脉导管相关血流感染方面做出了巨大努力,但它们仍然是全球住院患者面临的危及生命的并发症,具有较高的发病率和死亡率。新出现的抗生素耐药细菌和其他风险因素,包括患者合并症,使患者管理变得复杂。
这是在沙特阿拉伯东部省法赫德国王大学医院进行的一项单中心回顾性观察性研究。纳入 2015 年 1 月至 2020 年 12 月期间确诊的中心静脉导管相关血流感染住院患者。主要目的是研究病原体抗生素敏感性模式、共存合并症和其他与死亡率相关的风险因素的变化趋势。
共纳入 214 例确诊的中心静脉导管相关血流感染患者(CLABSI)。30 天死亡率为 33.6%。医疗、外科和儿科重症监护病房每 1000 个中心静脉导管日的感染率分别为 4.97、2.99 和 4.56 例/1000 个 CL 日。总体微生物学趋势显示革兰氏阴性病原体占主导地位,真菌性 CLABSI 持续增加,2020 年达到 24.0%,细菌性 CLABSI 中多药耐药率高达 47%。此外,研究表明,糖尿病、心血管疾病、肺部疾病、慢性肾脏病和存在≥3 种合并症与患者生存呈显著负相关(P<0.05)。
研究人群的微生物学趋势显示,念珠菌属引起的 CLABSI 稳步增加,革兰氏阴性病原体占主导地位。根据相关死亡率风险因素(包括患者合并症)对患者进行分层,将有助于降低 CLABSI 发生率并改善患者预后。